Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 1;10(9):e037576.
doi: 10.1136/bmjopen-2020-037576.

Prospective multicentre randomised trial comparing the efficacy and safety of single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) versus Roux-en-Y gastric bypass (RYGB): SADISLEEVE study protocol

Affiliations

Prospective multicentre randomised trial comparing the efficacy and safety of single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) versus Roux-en-Y gastric bypass (RYGB): SADISLEEVE study protocol

Maud Robert et al. BMJ Open. .

Abstract

Introduction: Despite the non-negligible weight loss failure rate at midterm, Roux-en-Y gastric bypass (RYGB) remains the reference procedure in the treatment of morbid obesity with metabolic comorbidities. A recently emerged procedure, the single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S), could be more effective on weight loss with similar morbidity and lower weight loss failure rate than RYGB. We propose the first randomised, open, multicentre superiority trial comparing the SADI-S to RYGB (SADISLEEVE).

Methods and analysis: The main objective is to demonstrate the superiority at 2 years after surgery of the SADI-S compared with RYGB in term of excess weight loss percentage. The secondary objectives are the evaluation of nutritional status, metabolic outcomes, overall complication rates and quality of life, within 2 years after surgery. Key inclusion criteria are obese patients with body mass index (BMI) ≥40 kg/m2 or ≥35 kg/m2 with at least one comorbid condition and candidate to a first bariatric procedure or after failure of sleeve gastrectomy. Patients randomised by minimisation in two arms, based on centre, surgery as a revisional procedure, presence of type 2 diabetes and BMI >50 kg/m2 will be included over 2 years.A sample size of 166 patients in each group will have a power of 90% to detect a probability of 0.603 that excess weight loss in the RYGB arm is less than excess weight loss in the SADI-S arm with a 5% two-sided significance level. With a drop-out rate of 10%, it will be necessary to include 183 patients per group.

Ethics and dissemination: The study was approved by Institutional Review Board of Centre Hospitalier Universitaire Morvan (CPP1089-HPS1). Study was also approved by the French national agency for drug safety (2018061500148). Results will be reported in peer-reviewed scientific journals.

Trial registration number: NCT03610256.

Keywords: clinical trials; nutrition & dietetics; surgery.

PubMed Disclaimer

Conflict of interest statement

Competing interests: DM-B reports personal fees from Maat Pharma outside of the submitted work. MR reports fees as a consultant from Medtronic and fees as an expert speaker from Gore outside of the submitted work.

Figures

Figure 1
Figure 1
Roux-en-Y gastric bypass.
Figure 2
Figure 2
Single anastomosis duodeno–ileal bypass with sleeve gastrectomy.
Figure 3
Figure 3
Participant timeline diagram. BMI, body mass index; %EBWL, excess body weight loss percentage; %EWL, excess weight loss percentage; HbA1c, glycated haemoglobin; HDL, high-density lipoproteins; LDL, low-density lipoproteins; GIQLI, Gastrointestinal Quality of Life Index; RYGB, Roux-en-Y gastric bypass; SADI-S, single anastomosis duodeno–ileal bypass with sleeve gastrectomy; SF, short form; SG, sleeve gastrectomy; TG, triglycerides.
Figure 4
Figure 4
Theorical and real inclusions curves. The blue curve shows the rate of expected hypothetical inclusions needed to complete recruitment on time (n=366). The red curve shows the real number of inclusions between October 2018 and January 2020 (n=178).

References

    1. Buchwald H, Estok R, Fahrbach K, et al. . Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122:248–56. 10.1016/j.amjmed.2008.09.041 - DOI - PubMed
    1. Buchwald H, Avidor Y, Braunwald E, et al. . Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724–37. 10.1001/jama.292.14.1724 - DOI - PubMed
    1. Sjöström L, Lindroos A-K, Peltonen M, et al. . Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683–93. 10.1056/NEJMoa035622 - DOI - PubMed
    1. Thereaux J, Lesuffleur T, Czernichow S, et al. . Long-term adverse events after sleeve gastrectomy or gastric bypass: a 7-year nationwide, observational, population-based, cohort study. Lancet Diabetes Endocrinol 2019;7:786–95. 10.1016/S2213-8587(19)30191-3 - DOI - PubMed
    1. Wittgrove AC, Clark GW, Tremblay LJ. Laparoscopic gastric bypass, Roux-en-Y: preliminary report of five cases. Obes Surg 1994;4:353–7. 10.1381/096089294765558331 - DOI - PubMed

Publication types

Associated data